Valuation: EyePoint, Inc.

Market Cap 1.13B 976M 915M 834M 1.57B 107B 1.59B 10.76B 4.2B 53.73B 4.22B 4.13B 179B P/E 2026 *
-3.42x
P/E 2027 * -4.37x
Enterprise Value 802M 696M 653M 595M 1.12B 76.47B 1.14B 7.68B 3B 38.32B 3.01B 2.95B 128B EV / Sales 2026 *
457x
EV / Sales 2027 * 34.8x
Free-Float
96.42%
Yield 2026 *
-
Yield 2027 * -
1 day+3.68%
1 week+15.94%
Current month+10.45%
1 month-8.08%
3 months-3.22%
6 months+5.29%
Current year-25.94%
1 week 12
Extreme 12.005
14.32
1 month 11.54
Extreme 11.54
14.72
Current year 11.3
Extreme 11.295
18.87
1 year 9.65
Extreme 9.65
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
41.5
Manager TitleAgeSince
Chief Executive Officer 67 2023-07-09
Director of Finance/CFO 61 2019-11-13
Chief Tech/Sci/R&D Officer 43 2024-03-03
Director TitleAgeSince
Director/Board Member 67 2023-07-09
Director/Board Member 80 2024-09-02
Director/Board Member 58 2019-07-14
Date Insider Type Main position Quantity % Market Cap.
7/10/26 Fiscal year

Chief Executive Officer

41,393 0.0494%
6/30/26 Fiscal year

Chief Technology Officer

14,625 0.0174%
3/23/26 Others

Chief Executive Officer

453,532 0.5478%
Change 5-day change 1-year change 3-year change Capi.($)
+3.68%+15.94%+31.68%-4.72% 1.13B
+0.43%+9.38%+92.10%+130.99% 1,083B
+0.41%+2.33%+50.07%+50.05% 626B
-0.53%+2.03%+25.23%+63.46% 442B
-0.92%+2.18%+48.40%+37.85% 363B
-1.32%-0.32%+29.35%+36.81% 295B
-1.20%-0.32%+6.03%+6.09% 248B
+0.45%+6.71%+45.98%+58.54% 224B
-2.51%-2.63%-7.16%-51.74% 210B
+0.07%+0.46%+12.78%+69.84% 168B
Average -0.14%+3.77%+33.45%+39.72% 366.02B
Weighted average by Cap. -0.26%+4.29%+49.44%+65.94%

Financials

2026 *2027 *
Net sales 1.75M 1.52M 1.43M 1.3M 2.45M 167M 2.49M 16.79M 6.55M 83.81M 6.59M 6.45M 280M 21.92M 19.02M 17.83M 16.24M 30.55M 2.09B 31.06M 210M 81.83M 1.05B 82.29M 80.5M 3.49B
Net income -344M -299M -280M -255M -479M -32.79B -487M -3.29B -1.28B -16.43B -1.29B -1.26B -54.83B -289M -251M -235M -215M -403M -27.59B -410M -2.77B -1.08B -13.83B -1.09B -1.06B -46.14B
Net Debt -323M -280M -263M -239M -450M -30.77B -457M -3.09B -1.21B -15.42B -1.21B -1.19B -51.45B -362M -314M -294M -268M -505M -34.5B -513M -3.46B -1.35B -17.29B -1.36B -1.33B -57.7B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
26-08-12 US$13.53 +3.68% 2,259,249
26-08-11 US$13.05 -0.15% 2,058,473
26-08-10 US$13.07 -5.90% 1,757,173
26-08-07 US$13.89 +8.26% 1,655,696
26-08-06 US$12.83 +4.73% 2,240,810
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
13.05USD
Average target price
40.93USD
Spread / Average Target
+213.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock